Jemperli

News

Gloved hand punches a karate pad held up

GSK unit and AnaptysBio trade lawsuits over Jemperli

A spat between GSK/Tesaro and AnaptysBio over cancer drug Jemperli has escalated into litigation, with both parties claiming breach of contract.

News

EU approves endometrial, lung cancer drugs from GSK and J&J

Both GSK and J&J have claimed pivotal approvals for growth-phase oncology therapies in the EU.

News

GSK bags sought-after Jemperli okay in endometrial cancer

The FDA has cleared GSK's PD-1 inhibitor Jemperli as a treatment for all adult patients with primary advanced or recurrent endometrial cancer, a key part of the company's growth ambitions f

News

OS data set up wider Jemperli use in endometrial cancer

GSK’s Jemperli has claimed an edge over its main rival in the endometrial cancer therapy market after showing improved overall survival in a broad patient population in th

News

NICE backs frontline use of Jemperli in endometrial cancer

GSK’s PD-1 inhibitor Jemperli has been cleared for use by the NHS as a first-line treatment for a specific type of endometrial cancer, making it an option for around 580 w

News

New RUBY readout buoys GSK’s Jemperli in endometrial cancer

GSK has said that a regimen of PD-1 inhibitor Jemperli with PARP inhibitor Zejula has shown efficacy in the second stage of the RUBY trial, which could open up wider use i

GSK unit and AnaptysBio trade lawsuits over Jemperli

EU approves endometrial, lung cancer drugs from GSK and J&J

GSK bags sought-after Jemperli okay in endometrial cancer

OS data set up wider Jemperli use in endometrial cancer

NICE backs frontline use of Jemperli in endometrial cancer

New RUBY readout buoys GSK’s Jemperli in endometrial cancer

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Jemperli

Editor's Picks